Hyundai Bioscience Co. Ltd (048410) - Total Assets
Based on the latest financial reports, Hyundai Bioscience Co. Ltd (048410) holds total assets worth ₩116.62 Billion KRW (≈ $79.03 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Hyundai Bioscience Co. Ltd (048410) net assets for net asset value and shareholders' equity analysis.
Hyundai Bioscience Co. Ltd - Total Assets Trend (2002–2024)
This chart illustrates how Hyundai Bioscience Co. Ltd's total assets have evolved over time, based on quarterly financial data.
Hyundai Bioscience Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hyundai Bioscience Co. Ltd's total assets of ₩116.62 Billion consist of 10.1% current assets and 89.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 5.4% |
| Accounts Receivable | ₩247.21 Million | 0.4% |
| Inventory | ₩1.08 Billion | 1.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩33.17 Billion | 49.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how Hyundai Bioscience Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Hyundai Bioscience Co. Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hyundai Bioscience Co. Ltd's current assets represent 10.1% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 5.4% of total assets in 2024, down from 9.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 2.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 49.0% of total assets.
Hyundai Bioscience Co. Ltd Competitors by Total Assets
Key competitors of Hyundai Bioscience Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Hyundai Bioscience Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.40 | 0.34 | 4.37 |
| Quick Ratio | 6.01 | 0.33 | 3.93 |
| Cash Ratio | 0.00 | 0.30 | 0.00 |
| Working Capital | ₩30.34 Billion | ₩-17.36 Billion | ₩32.28 Billion |
Hyundai Bioscience Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Hyundai Bioscience Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.50 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 28.2% |
| Total Assets | ₩67.70 Billion |
| Market Capitalization | $872.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hyundai Bioscience Co. Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Hyundai Bioscience Co. Ltd's assets grew by 28.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Hyundai Bioscience Co. Ltd (2002–2024)
The table below shows the annual total assets of Hyundai Bioscience Co. Ltd from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩67.70 Billion ≈ $45.88 Million |
+28.25% |
| 2023-12-31 | ₩52.79 Billion ≈ $35.78 Million |
-21.59% |
| 2022-12-31 | ₩67.33 Billion ≈ $45.63 Million |
-16.39% |
| 2021-12-31 | ₩80.53 Billion ≈ $54.57 Million |
-12.76% |
| 2020-12-31 | ₩92.31 Billion ≈ $62.56 Million |
+45.98% |
| 2019-12-31 | ₩63.24 Billion ≈ $42.85 Million |
+17.08% |
| 2018-12-31 | ₩54.01 Billion ≈ $36.60 Million |
+9.11% |
| 2017-12-31 | ₩49.50 Billion ≈ $33.54 Million |
-7.27% |
| 2016-12-31 | ₩53.38 Billion ≈ $36.18 Million |
+22.96% |
| 2015-12-31 | ₩43.41 Billion ≈ $29.42 Million |
+32.33% |
| 2014-12-31 | ₩32.81 Billion ≈ $22.23 Million |
+6.37% |
| 2013-12-31 | ₩30.84 Billion ≈ $20.90 Million |
-3.80% |
| 2012-12-31 | ₩32.06 Billion ≈ $21.73 Million |
+5.21% |
| 2011-12-31 | ₩30.47 Billion ≈ $20.65 Million |
-37.11% |
| 2010-12-31 | ₩48.45 Billion ≈ $32.83 Million |
-20.81% |
| 2009-12-31 | ₩61.19 Billion ≈ $41.46 Million |
-30.09% |
| 2008-12-31 | ₩87.53 Billion ≈ $59.31 Million |
-15.16% |
| 2007-12-31 | ₩103.16 Billion ≈ $69.91 Million |
-2.23% |
| 2006-12-31 | ₩105.52 Billion ≈ $71.51 Million |
-54.29% |
| 2005-12-31 | ₩230.83 Billion ≈ $156.43 Million |
+2.68% |
| 2004-12-31 | ₩224.80 Billion ≈ $152.34 Million |
-7.32% |
| 2003-12-31 | ₩242.55 Billion ≈ $164.37 Million |
+20.91% |
| 2002-12-31 | ₩200.60 Billion ≈ $135.94 Million |
-- |
About Hyundai Bioscience Co. Ltd
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.